CardiologyAlirocumabCardiac Allograft Vasculopathy
Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial
By MedXY|Dec 25, 2025
The CAVIAR trial reveals that while alirocumab significantly reduces LDL-C in heart transplant recipients, it does not arrest coronary plaque progression within the first year, suggesting that early cardiac allograft vasculopathy may be dri
